CA3019581A1 - Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies - Google Patents

Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies Download PDF

Info

Publication number
CA3019581A1
CA3019581A1 CA3019581A CA3019581A CA3019581A1 CA 3019581 A1 CA3019581 A1 CA 3019581A1 CA 3019581 A CA3019581 A CA 3019581A CA 3019581 A CA3019581 A CA 3019581A CA 3019581 A1 CA3019581 A1 CA 3019581A1
Authority
CA
Canada
Prior art keywords
antibody
antigen
cells
cell
flt3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3019581A
Other languages
English (en)
French (fr)
Inventor
Vladislav Sandler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hemogenyx Pharmaceuticals LLC
Original Assignee
Hemogenyx LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hemogenyx LLC filed Critical Hemogenyx LLC
Publication of CA3019581A1 publication Critical patent/CA3019581A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3019581A 2016-04-04 2017-04-04 Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies Pending CA3019581A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662317906P 2016-04-04 2016-04-04
US62/317,906 2016-04-04
PCT/US2017/025951 WO2017176760A2 (en) 2016-04-04 2017-04-04 Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies

Publications (1)

Publication Number Publication Date
CA3019581A1 true CA3019581A1 (en) 2017-10-12

Family

ID=60001426

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3019581A Pending CA3019581A1 (en) 2016-04-04 2017-04-04 Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies

Country Status (6)

Country Link
US (2) US11021536B2 (https=)
EP (1) EP3439699A4 (https=)
JP (1) JP2019513836A (https=)
CN (1) CN109562164B (https=)
CA (1) CA3019581A1 (https=)
WO (1) WO2017176760A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3105252T3 (da) * 2014-02-12 2019-10-14 Michael Uhlin Bispecifikke antistoffer til anvendelse ved stamcelletransplantation
US11104738B2 (en) 2016-04-04 2021-08-31 Hemogenyx Pharmaceuticals Llc Monoclonal antibodies to human FLT3/FLK2 receptor protein
WO2017176760A2 (en) 2016-04-04 2017-10-12 Vladislav Sandler Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies
EP3623383A1 (en) * 2018-09-11 2020-03-18 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Improved bispecific flt3xcd3 antigen binding proteins
CN113056486B (zh) 2018-09-11 2025-06-17 德国肿瘤研究中心 改善的抗flt3抗原结合蛋白
JP7642542B2 (ja) 2018-12-18 2025-03-10 ベーリンガー・インゲルハイム・イオ・カナダ・インコーポレイテッド Ｆｌｔ３アゴニスト抗体及びその使用
EP3962527A4 (en) 2019-04-30 2023-11-01 Senti Biosciences, Inc. CHIMERIC RECEPTORS AND METHODS OF USE THEREOF
WO2021007266A1 (en) * 2019-07-09 2021-01-14 Hemogenyx Llc Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies
WO2023023491A1 (en) 2021-08-16 2023-02-23 Hemogenyx Pharmaceuticals Llc Anti-flt3 antibodies, cars, car t cells and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
HRP20160422T1 (hr) * 2009-12-23 2016-05-20 Synimmune Gmbh Protutijela protiv flt3 postupci njihove upotrebe
LT2794658T (lt) * 2011-12-19 2017-05-10 Synimmune Gmbh Bispecifinė antikūno molekulė
EP2985294A1 (en) 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
ES2869972T3 (es) 2015-01-26 2021-10-26 Cellectis Sistemas de receptores de antígenos quiméricos dirigidos por mAb para clasificar/agotar células inmunitarias genomanipuladas
WO2016172026A1 (en) 2015-04-20 2016-10-27 The Board Of Regents Of The University Of Texas System Clec11a is a bone growth agent
US11104738B2 (en) 2016-04-04 2021-08-31 Hemogenyx Pharmaceuticals Llc Monoclonal antibodies to human FLT3/FLK2 receptor protein
WO2017176760A2 (en) 2016-04-04 2017-10-12 Vladislav Sandler Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies
CN109641051A (zh) 2016-06-17 2019-04-16 美真达治疗公司 用于耗尽细胞的组合物和方法
EP3612568B8 (en) 2017-04-18 2021-12-08 Autolus Limited Cell

Also Published As

Publication number Publication date
EP3439699A4 (en) 2019-11-20
WO2017176760A2 (en) 2017-10-12
CN109562164A (zh) 2019-04-02
US11945866B2 (en) 2024-04-02
US20190127464A1 (en) 2019-05-02
US11021536B2 (en) 2021-06-01
JP2019513836A (ja) 2019-05-30
WO2017176760A3 (en) 2017-11-16
EP3439699A2 (en) 2019-02-13
CN109562164B (zh) 2022-10-04
US20210188978A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
US11945866B2 (en) Method of eliminating hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in a patient using bi-specific antibodies
Hu et al. Cancer immunotherapy based on natural killer cells: current progress and new opportunities
US20220204935A1 (en) Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
AU2020384369B2 (en) Anti-TCR antibody molecules and uses thereof
Tettamanti et al. Targeting of acute myeloid leukaemia by cytokine‐induced killer cells redirected with a novel CD 123‐specific chimeric antigen receptor
US11104738B2 (en) Monoclonal antibodies to human FLT3/FLK2 receptor protein
CN105873952A (zh) 经修饰的造血干细胞/祖细胞和非t效应细胞及其用途
JP2006528627A (ja) アロ反応性ナチュラルキラー細胞を使用する治療用抗体の有効性を増加するための方法および組成物
US20230218669A1 (en) Augmenting antigen-negative cell death in antigen-targeted immunotherapies
WO2022092277A1 (ja) Ｃｘｃｌ１２受容体発現キメラ抗原受容体（ｃａｒ）－ｔ細胞
CA3146912A1 (en) Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies
EP4378953A1 (en) Cd229 targeting moiety for the tratment of cd229 positive cancer
CN118284621A (zh) 抗flt3抗体、car、car t细胞和使用方法
KR102919638B1 (ko) 자연살해세포 및 car-nk 세포의 제조 방법, 이에 따라 제조된 자연살해세포 및 car-nk 세포, 및 이의 용도
Minina et al. CAR cells beyond classical CAR T cells: functional properties and prospects of application
US20240216432A1 (en) Anti-flt3 antibodies, cars, car t cells and methods of use
TWI917318B (zh) 靶向ｄｌｌ３的嵌合抗原受體和結合劑
RU2828787C2 (ru) Способы получения аллогенных t-клеток с car
HK40074429A (en) Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
KR20250060146A (ko) 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220311